Introduction
Much has been written in recent years about the treatment of acute lymphoblastic leukaemia, in which the aim is now to eradicate the disease with the hope of permanent cure. The situation in acute myelogenous leukaemia is differeit. Until recently, it was rare to obtain complete remissions in this disease and difficult to maintain them for any length of time. There are now several regimens in existence which produce complete remissions in about half of the patients. We have used a combination of daunorubicin and cytosine arabinoside which, when used as single agents, give a higher percentage of remissions than any other single agent, and our preliminary results in 37 patients were reported by Crowther et al. (1970) .
The purpose of this paper is to record our experience at St. Bartholomew's Hospital of treating 94 patients since 1969 with these two drugs, because they highlight many of the difficulties. Firstly, the difficulty of obtaining a remission and the complications which arise during this time; secondly, the problems arising during the maintenance of remission; thirdly, the problem of those who do not remit; and, finally, the treatment of the relapsed patients.
Materials and Methods
Patients.-Altogether, 94 unselected patients with acute myelogenous leukaemia have been admitted to three trials since May 1969, with 40 patients in trial 1, 22 in trial 2, and 32 in trial 3. The type of acute leukaemia present in these patients is given in table I. There were 56 with acute myeloblastic leukaemia, 23 with acute myelomonoblastic leukaemia, six with acute promyelocytic leukaemia, eight with erythroleukaemia, and one with acute monoblastic leukaemia. No patients were excluded from the first two trials, but three patients were excluded from trial 3 because one had received previous therapy with daunorubicin and cytosine arabinoside, another refused treatment and discharged himself on the day of admission to hospital, and, in the third patient, there was an error in diagnosing the type of leukaemia. In nearly all patients a diagnosis of acute myelogenous leukaemia was confirmed within a few hours of admission. Chemotherapy usually started on the evening of admission, but in a few patients treatment was postponed for 132 . 4 (1) 2 (1) 2 ( Definition of Remission.-Complete remission was judged to have occurred when the patient became asymptomatic, clinically free from disease, the bone marrow cellularity was normal, there were no abnormal blast cells in the marrow and less than 5% of apparently normal blast cells, the peripheral blood count showed a haemoglobin level greater than 12 g/100 ml not maintained by transfusion, a white blood count greater than 3,000/mm3 with a normal differential count and neutrophils numbering more than 1,500/mm3 and a platelet count above 100,000/mm3. These are the criteria for complete remission used by the Midwest Cooperative Chemotherapy Study Group (Hewlett et al. 1964) . The remission lengths were estimated from the date of complete remission (Ml) bone marrow to the date of haematological relapse. There were no remissions terminated by central nervous system leukaemia in this series.
INITIAL CHEMOTHERAPY
In each of the three trials, daunorubicin and cytosine arabinoside were the two drugs used for inducing a remission but were given in a different way in trial 2 from trials 1 and 3.
Trials 1 and 3
The chemotherapy is set out in fig. 1 . It consisted of five-day courses of daunorubicin 1-5 mg/kg body weight (55 mg/M2) given by fast intravenous infusion on day 1, and cytosine arabinoside 2 mg/kg body weight (70 mg/M2) given on days 1 to 5 by intravenous injection every 24 hours. Courses were repeated at intervals of about 10 days until remission was achieved. Immunotherapy Reagents used were B.C.G. and irradiated leukaemic cells. The B.C.G. used in all trials was the Glaxo freeze-dried percutaneous vaccine (moist weight 10 mg/ml; 150-750 x 106 viable organisms/ml). The total bacterial count was about five times the viable count. The Pasteur liquid vaccine has a lower concentration of live organisms (about 50 x 106 viable organisms/ml), but the moist weight is much higher (75 mg/ml). It has been estimated that when using the multipuncture technique with 40 needle punctures set to a depth of 2 mm, the number of viable organisms introduced is in the same order of magnitude as Mathe et al. (1969) obtained using the Pasteur liquid vaccine and the scarification technique, but the latter is accompanied by a more severe local inflammatory reaction than the multipuncture technique. The 40 puncture technique was used in the M.R.C. trial of immunotherapy in acute lymphoblastic leukaemia (1971) .
Leukaemia cells for immunotherapy were obtained from the peripheral blood of untreated patients with acute myelogenous leukaemia by using an I.B.M. cell separator (Buckner et al., 1959; Powles et al., 1971) . These cells were stored at -179°C in a viable state and before injection were rapidly thawed, washed, and irradiated to 10,000 rads.
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Method of Giving Immunotherapy In trial 1, three types of immunotherapy were used-intradermal B.C.G., autologous irradiated leukaemic cells, and a combination of B.C.G. and allogeneic irradiated leukaemic cells. The immunotherapy was given at weekly intervals. B.C.G. was given by one of three methods. The first method used a Heaf gun which was applied 10 times (60 needle punctures) at 2 mm penetration, and the second involved 20 scarifications, each 10 cm long, in a similar way to that described by Mathe et al. (1969) . In the four patients receiving B.C.G. alone, both these methods were used on different arms in the same patient. The third method was used in all patients receiving allogeneic leukaemic cells and involved a 20-needle multiple puncture gun set to a depth of 2 mm and fired twice. It was calculated that the latter method would deliver about one million viable organisms intradermally, but this estimate is subject to considerable error.
Irradiated leukaemic cells were given by weekly subcutaneous and intradermal injections, 109 cells being distributed between three limbs, and if B.C.G. was used in addition this was given in the fourth limb. The sites of injection into the four litnbs were rotated each week.
In trials 2 and 3 only one combination of immunotherapy was used-B.C.G. by the 20-needle multiple puncture gun and allogeneic irradiated leukaemic cells each week.
Supportive Care Bacteriological investigations were carried out on the urine, blood, swabs of the nose, throat, and any obviously infected region in patients with fever. During the course of treatment the aim was to start antibiotic therapy within one hour of a fever being noticed. Ampicillin and cloxacillin were usually used initially if there was no obvious site of infection. Gentamycin with carbenicillin or cephaloridine were used if a Gram-negative infection was suspected. The appropriate antibiotic was used when the results of bacteriological studies were known. Oral antibiotics were used where possible in patients who, in spite of the fever, remained clinically well. Prophylactic antibiotic therapy was not used, but prophylactic antifungal agents were regarded as necessary to limit the growth of candida in the mouth, which frequently occurred in these susceptible patients. All patients were nursed in open general medical wards; no "isolation units" were used. Anaemia was treated where necessary by transfusion of packed red cells from stored blood, and fresh whole donor blood was given for severe haemorrhage. Thrombocytopenia accompanied by haemorrhage was treated with fresh ABO compatible platelet transfusions from random donors at a dose of 4 units per m2 at each transfusion. Platelet transfusions were not used prophylactically in the absence of haemorrhage from mucosal surfaces, but extensive retinal or skin haemorrhage was considered to be an indication for their use. Allopurinol was given routinely to prevent hyperuricaemia during remission induction in a dose of 300 mg daily by mouth.
Results

REMISSION INDUCTION
The number of patients who achieved a complete remission in the three trials is shown in table 1. In trials 1 and 3 where the patients received the same induction programme ( fig. 1) , 39 of 72 patients had complete remissions (54%) and a further six had useful partial remissions. Ten patients in trial 1 received L-asparaginase in addition to daunorubicin and cytosine arabinoside. The L-asparaginase was given at a dose of 30,000 units/m2 daily for a period of up to 28 days. We have described previously how this drug increased the side effects of treatment without altering the remission rate (Crowther et al., 1970) .
When using the different drug schedule in trial 2, only seven outof22-patients (32%) achieved a complete remission, but this group of patients was not entirely comparable due to age distribution (see below). There is no doubt that in acute myelogenous leukaemia, unlike lymphoblastic leukaemia, a period of severe marrow hypoplasia must occur before a complete remission is obtained. We have no patients in whom a complete remission was obtained who did not have pancytopenia due to marrow hypoplasia. The early deaths represent a failure to prevent the fatal effects of pancytopenia in a significant number of patients.
The treatment chart in fig. 4 is that of a typical patient which shows two important features. First, there is the inevitable pancytopenic phase lasting about four weeks, and then there is the recovery phase when the counts steadily return to normal levels despite continuing chemotherapy. It is quite clear that the effect of these drugs on a marrow infiltrated with leukaemia is BRITISH MEDICAL JOURNAL 20 JANUARY 1973 quite different from that on a normal marrow. The first course caused a fall in the platelet and neutrophil counts but subsequent courses once remission had occurred had no significant effect on the counts. Altogether, 21 out of the 72 patients (29%) in trials 1 and 3 died during the first month of treatment, compared with 10 out of the 22 patients (46%) in trial 2. The complete remission rate of patients in trials 1 and 3 who survived the first month of treat-. ment was 39 out of 51 (77%). Only seven out of 12 patients (58%) in trial 2 analysed in the same way achieved a complete remission. Although the number of patients is small, the altered drug schedule used in trial 2 did not appear to offer any advantage over the schedule used in trial 1, and this was the reason why, in trial 3, we reverted to the remission induction regimen of trial 1. With both regimens, on average, three courses were required to produce a remission.
Age
The age of a patient was an important factor influencing response to treatment. The age distribution of all 94 patients in the series is shown in fig. 5 . The median age was 50 years. Sixty-eight patients were below 60 years of age at presentation, and 40 of these obtained complete remissions (59%). None of the nine patients over 70 years old and only six out of the 26 patients aged 60 years or more achieved complete remissions (23%). 
Initial Platelet Count
The platelet count estimated at the time of admission to St. Bartholomew's Hospital was related to the incidence of complete remission in the 94 patients, as shown in table III. There was a significant difference in remission rates between patients presenting with a platelet count of less than 20,0001mmn and those with an initial platelet count greater than this (P 0-05). A total of 55% of patients with platelet counts of more than 20,000/mm8 achieved remissions, whereas only 29% of patients with platelet counts below this figure obtained remissions. Of those who had not received earlier chemotherapy, four out of 11 achieved complete remissions in the low platelet group and 26 out of 55 with platelet counts in the higher group. remission was 50 weeks. The median survival for the 48 patients who failed to achieve a remission in trials 1, 2, and 3 was less than one month. This emphasizes the known importance of remission induction on survival in this disease.
Complete follow-up data on all patients in trials 1, 2, and 3 up to 1 October 1972 is given in fig. 7 . The patients receiving all forms of immunotherapy as a collective group in trial 1 had similar remissions lengths to those receiving mercaptopurine and methotrexate maintenance ( fig. 8) Other series have been reported with remission rates in the region of 50%, but fewer patients were studied. For example, Rosenthal and Moloney (1972) BRITISH MEDICAL JOURNAL 20 JANUARY 1973 137 the elderly with acute myelogenous leukaemia, the response rate is much lower than in younger patients. We feel that the combination of daunorubicin and cytosine arabinoside remains as good, if not better, than any other drug combination used for remission induction in adult acute myelogenous leukaemia. The schedule is simple, and both drugs are given by intravenous administration, which means that timing and drug dosage are accurate. The timing of drug administration may well be critical if optimum results are to be obtained, and comparisons between different series suffer from the difficulty that the drug schedules are not usually comparable, even when the same drugs are given. The South-West Co-operative Chemotherapy Group has found that the remission rate was significantly higher (P 0 05) when cytosine arabinoside was administered by continuous infusion over a period of 120 hours than when the drug was given continuously over 48 hours (Freireich et al., 1971) . Although our remission rate appeared lower in the 22 patients treated in trial 2 with the altered drug schedule, this may have been because of the age difference in the two groups.
The importance of supportive care during remission induction has already been emphasized. All patients who achieved remissions in this series underwent a variable period of severe pancytopenia and bone marrow hypoplasia. During this time many patients became very ill, and without correct supportive care would have died. Graw et al. (1972) Altogether, 31 of our 92 patients died within the first month and a further 17 failed to achieve a complete remission, and must be regarded as initial treatment failures. The 17 who survived the first month but failed to remit were treated with thioguanine, cyclophosphamide, mercaptopurine, adriamycin, or prednisolone, either singly or in combination, but none achieved a complete remission and they are all now dead. Failure to support the patients during the initial weeks of treatment and the inability to achieve remissions with other drugs when the initial treatment with daunorubicin and cytosine arabinoside has failed remain the two major problems to be solved before the remission rate in acute myelogenous leukaemia can be significantly improved.
REMISSION MAINTENANCE
Until very recently the results of maintaining remissions in acute myelogenous leukaemia have been poor. Whitecar et al. (1972) , however, reported a median remission length of 42 weeks in a series of 17 patients maintained on intermittent combination chemotherapy using cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP). A preliminary report by Clarkson (1972) has indicated that their remission lengths after the L6 protocol, which involves the sequential use of many drugs, are also promising; of 28 patients achieving remissions on the L6 protocol, 18 were continuing in remission for 2 -t to 24-t months, five of them for over 12 months. The results appear comparable to our patients maintained with intermittent chemotherapy and immunotherapy in trials 2 and 3, and better than our chemotherapy-only group.
To our knowledge, there have been no other published studies involving the use of active specific and non-specific immunotherapy in patients with acute myelogenous leukaemia. These preliminary follow-up data on a small number of patients show promising results in favour of combined intermittent chemotherapy and immunotherapy in these forms of acute leukaemia. A previous study by Mathe and his colleagues (1969) using B.C.G. (Pasteur liquid vaccine) alone, B .C.G. with irradiated allogeneic leukaemic cells, or irradiated leukaemic cells alone as immunotherapy in patients with acute lymphoblastic leukaemia, showed some improvement in remission lengths, but the numbers were small, and eventually all patients received both. As in this series, the control group contained only 10 patients, and further studies are required before any benefits of immunotherapy can be clearly assessed. Until there is clear confirmation that immunotherapy has a definite part in prolonging survival in a large carefully controlled group of patients it must be regarded as an experimental procedure. This study is continuing in the hope that our preliminary results may be confirmed with a large number of patients.
A study such as this would have been impossible without the full co-operation from departments concerned with general medical care. The personnel of departments of radiology and pathology have provided helpful advice throughout the trials.
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